Cannabidiol - Avicanna
Alternative Names: TruneroxLatest Information Update: 26 Jun 2024
At a glance
- Originator Avicanna
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Seizures
Most Recent Events
- 19 Jun 2024 Avicanna has patent protection for self-emulsifying drug delivery system (SEDDS) oral cannabinoid compositions and methods for treating neuropathic pain in USA
- 13 Feb 2024 Registered for Seizures (Adjunctive treatment) in Colombia (PO)
- 13 Feb 2024 Avicanna expects marketing authorization in Brazil and other South American markets during 2024 (Avicanna pipeline, February 2024)